BC Innovations | Jul 10, 2018
Distillery Therapeutics


INDICATION: Blistering disorder Patient sample and cell culture studies suggest the generic antibiotic gentamicin could help treat Herlitz junctional epidermolysis bullosa, a blistering disorder caused by loss-of-function mutations in LAMB3. In patient-derived junctional epidermolysis cells...
BC Innovations | Nov 30, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: November 2017

New Therapeutic Targets and Biomarkers: November 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during November 2017. Therapeutic targets are defined as any protein, gene or other...
BC Extra | Nov 9, 2017
Preclinical News

LAMB3 gene therapy successfully treats epidermolysis bullosa

In a paper published in Nature , researchers from Ruhr University Bochum and colleagues described the successful regeneration and engraftment of almost the entire epidermis of a patient with junctional epidermolysis bullosa (JEB) using laminin beta...
Items per page:
1 - 3 of 3